Newsroom Archives - Page 16 of 24 - Spectral Medical Inc

Spectral to Present at Investor Summit Group’s Q2 In-Person Conference on May 3rd in NYC

TORONTO, Canada –April 27, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Spectral Medical Announces Appointment of Blair McInnis as CFO

TORONTO, Canada – March 21, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Dialco Medical Announces Formation of Medical Advisory Board to Support the Continued Development of DIMI Device.

TORONTO, Canada – March 16, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly owned subsidiary, Dialco Medical Inc. (“Dialco”) has formed a Medical Advisory Board to support in guiding the DIMI usability trial and...

Spectral Medical CMO Dr. John Kellum to Present at the 27th International AKI & CRRT Conference on March 7-10, 2022

TORONTO, Canada – March 4, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Spectral Medical Reports Progress on Tigris Clinical Trial

Patient mortality data continues to exceed expectationsRecent FDA approved SOFA amendment contributing to increased patient enrollment TORONTO, Canada – February 11, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic...

Spectral Medical Announces U.S. FDA Approval of DIMI Trial Protocol Amendment

Amendment expected to overcome key pandemic challenges and improve both site and patient enrollment TORONTO, Canada – January 31, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.